TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Results of Operations and Financial Condition
On May 5, 2017, TG Therapeutics, Inc. TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the first quarter ended March 31, 2017. TG also announced that on Friday, May 5, 2017 at 8:30am ET, TG would host an investor conference call during which the Company would provide a brief overview of its first quarter financial results and provide a business outlook for the remainder of 2017. A copy of such press release is being furnished as Exhibit 99.1.
Item 9.01 Financial Statements And Exhibits.
(d) Exhibits.
99.1
Press release issued by TG Therapeutics, Inc., dated May 5, 2017.
– 2 –
About TG Therapeutics, Inc. (NASDAQ:TGTX)
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities. TG Therapeutics, Inc. (NASDAQ:TGTX) Recent Trading Information
TG Therapeutics, Inc. (NASDAQ:TGTX) closed its last trading session down -0.30 at 10.15 with 1,193,601 shares trading hands.
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities. TG Therapeutics, Inc. (NASDAQ:TGTX) Recent Trading Information
TG Therapeutics, Inc. (NASDAQ:TGTX) closed its last trading session down -0.30 at 10.15 with 1,193,601 shares trading hands.
